218 related articles for article (PubMed ID: 12465466)
1. Safety considerations in vector development.
Kappes JC; Wu X
Somat Cell Mol Genet; 2001 Nov; 26(1-6):147-58. PubMed ID: 12465466
[TBL] [Abstract][Full Text] [Related]
2. Development of a novel trans-lentiviral vector that affords predictable safety.
Wu X; Wakefield JK; Liu H; Xiao H; Kralovics R; Prchal JT; Kappes JC
Mol Ther; 2000 Jul; 2(1):47-55. PubMed ID: 10899827
[TBL] [Abstract][Full Text] [Related]
3. Analysis of lenti- and trans-lentiviral vector genetic recombination.
Wu X; Wakefield JK; Liu H; Kappes JC
Dev Biol (Basel); 2001; 106():237-48; discussion 249, 253-63. PubMed ID: 11761237
[TBL] [Abstract][Full Text] [Related]
4. Production of lentiviral vectors for transducing cells from the central nervous system.
Li M; Husic N; Lin Y; Snider BJ
J Vis Exp; 2012 May; (63):e4031. PubMed ID: 22664962
[TBL] [Abstract][Full Text] [Related]
5. Characterization of recombination events leading to the production of an ecotropic replication-competent retrovirus in a GP+envAM12-derived producer cell line.
Garrett E; Miller AR; Goldman JM; Apperley JF; Melo JV
Virology; 2000 Jan; 266(1):170-9. PubMed ID: 10612671
[TBL] [Abstract][Full Text] [Related]
6. Construction of a retroviral vector production system with the minimum possibility of a homologous recombination.
Yu SS; Han E; Hong Y; Lee JT; Kim S; Kim S
Gene Ther; 2003 Apr; 10(8):706-11. PubMed ID: 12692599
[TBL] [Abstract][Full Text] [Related]
7. A third-generation lentivirus vector with a conditional packaging system.
Dull T; Zufferey R; Kelly M; Mandel RJ; Nguyen M; Trono D; Naldini L
J Virol; 1998 Nov; 72(11):8463-71. PubMed ID: 9765382
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a replication-competent retrovirus resulting from recombination of packaging and vector sequences.
Otto E; Jones-Trower A; Vanin EF; Stambaugh K; Mueller SN; Anderson WF; McGarrity GJ
Hum Gene Ther; 1994 May; 5(5):567-75. PubMed ID: 8054374
[TBL] [Abstract][Full Text] [Related]
9. Design of a trans protease lentiviral packaging system that produces high titer virus.
Westerman KA; Ao Z; Cohen EA; Leboulch P
Retrovirology; 2007 Dec; 4():96. PubMed ID: 18163907
[TBL] [Abstract][Full Text] [Related]
10. A new-generation stable inducible packaging cell line for lentiviral vectors.
Farson D; Witt R; McGuinness R; Dull T; Kelly M; Song J; Radeke R; Bukovsky A; Consiglio A; Naldini L
Hum Gene Ther; 2001 May; 12(8):981-97. PubMed ID: 11387062
[TBL] [Abstract][Full Text] [Related]
11. A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors.
Cockrell AS; Ma H; Fu K; McCown TJ; Kafri T
Mol Ther; 2006 Aug; 14(2):276-84. PubMed ID: 16516556
[TBL] [Abstract][Full Text] [Related]
12. Influence of vector design and host cell on the mechanism of recombination and emergence of mutant subpopulations of replicating retroviral vectors.
Paar M; Klein D; Salmons B; Günzburg WH; Renner M; Portsmouth D
BMC Mol Biol; 2009 Feb; 10():8. PubMed ID: 19203366
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system.
Chang LJ; Urlacher V; Iwakuma T; Cui Y; Zucali J
Gene Ther; 1999 May; 6(5):715-28. PubMed ID: 10505094
[TBL] [Abstract][Full Text] [Related]
14. Lentiviral vectors that carry anti-HIV shRNAs: problems and solutions.
ter Brake O; Berkhout B
J Gene Med; 2007 Sep; 9(9):743-50. PubMed ID: 17628029
[TBL] [Abstract][Full Text] [Related]
15. Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol.
Lu X; Humeau L; Slepushkin V; Binder G; Yu Q; Slepushkina T; Chen Z; Merling R; Davis B; Chang YN; Dropulic B
J Gene Med; 2004 Sep; 6(9):963-73. PubMed ID: 15352069
[TBL] [Abstract][Full Text] [Related]
16. A synthetic Rev-independent bovine immunodeficiency virus-based packaging construct.
Molina RP; Ye HQ; Brady J; Zhang J; Zimmerman H; Kaleko M; Luo T
Hum Gene Ther; 2004 Sep; 15(9):865-77. PubMed ID: 15353041
[TBL] [Abstract][Full Text] [Related]
17. Chimeric HIV-1 and HIV-2 lentiviral vectors with added safety insurance.
Sachdeva G; D'Costa J; Cho JE; Kachapati K; Choudhry V; Arya SK
J Med Virol; 2007 Feb; 79(2):118-26. PubMed ID: 17177309
[TBL] [Abstract][Full Text] [Related]
18. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B
J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055
[TBL] [Abstract][Full Text] [Related]
19. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors.
Wagner R; Graf M; Bieler K; Wolf H; Grunwald T; Foley P; Uberla K
Hum Gene Ther; 2000 Nov; 11(17):2403-13. PubMed ID: 11096444
[TBL] [Abstract][Full Text] [Related]
20. Analysis of partial recombinants in lentiviral vector preparations.
Kuate S; Marino MP; Reiser J
Hum Gene Ther Methods; 2014 Apr; 25(2):126-35. PubMed ID: 24367910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
